

116. Elevated Resolvin D1 Predicts Plaque Rupture in Patients With Acute Myocardial Infarction: An Optical Coherence Tomography Study

Runzhen Chen, Hanjun Zhao, Hongbing Yan, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, China


Body

Background: Resolvin D1 (RvD1) has been demonstrated to inhibit atherosclerosis in animal models. However, its concentration in human plasma and impacts on coronary atherosclerotic plaques remains unclear. This study aimed to investigate the associations between RvD1 levels and plaque types in patients with acute myocardial infarction (AMI).

Methods: A total of 240 AMI patients undergoing optical coherence tomography (OCT) examination was analyzed. Patients were stratified by the median of RvD1 measured from the blood samples collected at admission. Univariable logistic regression was used to identify independent predictors of plaque rupture (PR), followed by multiple adjustment. The area under the curve (AUC), net reclassification index (NRI) and integrated discrimination improvement (IDI) was calculated to assess the additional predictive value of RvD1 of PR.

Results: Among the included patients, 121 (50.4 %) patients presented with PR. Patients with higher RvD1 (≥ 129.7 pg/mL) showed higher prevalence of PR (57.5 % vs 41.7 %, $P = 0.014$) and thinner fibrous cap (90 [60-120] μm vs 100 [70-140] μm , $P = 0.022$) as compared to those with lower RvD1 (< 129.7 pg/mL). Higher RvD1 was independent predictor of PR (odds ratio: 1.76, 95% confidence interval: 1.02-3.02, $P = 0.041$) after adjustment for other significant risk factors ($P < 0.1$) identified in univariable analysis (i.e., age, diabetes, platelet, culprit lesion at right coronary artery). The addition of RvD1 to models of clinical risk factors increased the accuracy for prediction of PR (NRI: 0.32, $P = 0.014$; IDI = 0.02, $P = 0.032$).


Conclusion: Elevated RvD1 is associated with PR and thinner fibrous cap, and could be a potential biomarker for prediction of PR.



| Factors | Univariable analysis | P-value | Multivariable analysis | P-value |
|----------------------------|----------------------|---------|------------------------|---------|
| | OR (95% CI) | | OR (95% CI) | |
| RvD1 (≥ 129.7 pg/ml) | 1.89 (1.13-3.16) | 0.015 | 1.76 (1.02-3.02) | 0.041 |
| Age, years | 1.02 (1.01-1.05) | 0.012 | 1.02 (1.00-1.05) | 0.068 |
| Diabetes | 1.84 (1.06-3.21) | 0.030 | 1.90 (1.06-3.43) | 0.032 |
| Platelet, $\times 10^9/L$ | 0.99 (0.98-0.99) | 0.002 | 0.99 (0.99-1.00) | 0.024 |
| Culprit lesion at RCA | 1.98 (1.15-3.41) | 0.014 | 1.94 (1.13-3.36) | 0.017 |

Table 1 (\uparrow). Logistic regression for predictors of plaque rupture. RvD1, resolving D1; RCA, right coronary artery.

Figure 2 (\rightarrow). Receiver operating curve for resolving D1 (RvD1) and clinical risk factors to predict plaque rupture. NRI, net reclassification index; IDI, integrated discrimination improvement.



Clinical Implications: better understand the role of anti-inflammatory agent RvD1 in the pathogenesis of atherosclerosis, and was the first to report RvD1 relevant data in AMI patients.